State Street’s Titan Pharmaceuticals TTNP Stock Holding History

State Street’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,914	Closed	-$15.8K	–	4404
2023 Q4	$15.8K	Hold	1,914	–	–	﹤0.01%	4362
2023 Q3	$17.8K	Hold	1,914	–	–	﹤0.01%	4456
2023 Q2	$24.8K	Hold	1,914	–	–	﹤0.01%	4565
2023 Q1	$31.7K	Hold	1,914	–	–	﹤0.01%	4612
2022 Q4	$30K	Hold	1,914	–	–	﹤0.01%	4669
2022 Q3	$41K	Buy	+1,914	New	+$49.4K	﹤0.01%	4699
2017 Q3	–	Sell	-68	Closed	-$467K	–	3767
2017 Q2	$467K	Sell	68 -13	-16%	-$121K	﹤0.01%	3428
2017 Q1	$963K	Hold	81	–	–	﹤0.01%	3278
2016 Q4	$1.17M	Sell	81 -6	-7%	-$101K	﹤0.01%	3248
2016 Q3	$1.84M	Buy	87 +4	+5%	+$77.7K	﹤0.01%	3000
2016 Q2	$1.63M	Buy	+83	New	+$1.77M	﹤0.01%	3105

Other funds holding TTNP

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GWSA

Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

State Street's TTNP Position: Q1 2024 in Review

State Street sold out of Titan Pharmaceuticals (TTNP) in Q1 2024, closing a stake of 1,914 shares — an estimated $15.8K sold.

State Street first reported a position in TTNP in Q2 2016 and held it in 11 quarters. The position peaked at $1.84M in Q3 2016. 17 funds tracked by Wall St. Rank hold TTNP as of Q1 2024.

State Street reported no remaining Titan Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
State Street sold 1,914 Titan Pharmaceuticals shares in Q1 2024, an estimated $15.8K.
State Street first reported a position in Titan Pharmaceuticals in Q2 2016 and held it in 11 quarters.
State Street's Titan Pharmaceuticals position peaked at $1.84M in Q3 2016.
17 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2024.

Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.